Search

Issue
Title
Authors
Novel therapies for the metastatic HER2-positive breast cancer with metastases in the central nervous system: a clinical case
Radyukova I.M., Rats N.M.
Breast cancer: from guidelines to personalized oncology
PierFranco C., Valentina G.
Optimal duration of adjuvant trastuzumab therapy in patients with HER2-possitive early breast cancer: whether the problem is resolved?
Zhukova L.G., Ganshina I.P., Khatkova E.I., Tikhomirova T.E., Kondratyeva O.E.
High efficiency of lapatinib in combination with capecitabine in patient with metastatic HER2-positive synchronous breast cancer (case study)
Seryakov A.P., Ovchinnikova L.K., Zabelin M.V., Yakubov T.Z., Sidorov D.B., Ovchinnikov M.V.
Pharmacoeconomic aspects of biosimilars
Tryakin A.A., Rudakova A.V., Fogt S.N., Vaganov A.S., Tolkacheva D.G.
Bioequivalence assessment of BCD-022 (trastuzumab, manufactured by JSC BIOCAD, Russia) as compared with Herceptin® (F.Hoffmann-La Roche Ltd., Switzerland), used in combination with paclitaxel in HER2-positive metastatic breast cancer patients: findings of the international, double-blind phase III clinical study
Ignatova E.O., Burdaeva O.N., Kopp M.V., Kotiv B.N., Udovitsa D.P., Stroiakovskii D.L., Alekseev S.M., Sheveleva L.P., Khorinko A.V., Shapovalova I.S., Moiseenko V.M., Ivanov R.A.
Current approach to adjuvant therapy for breast cancer (a review)
Conte P., Guarneri V.
Neoadjuvant systemic therapy of HER2-positive breast cancer
Frolova M.A.
Evolution of anti-HER2 therapy in advanced HER2+ breast cancer or “why is trastuzumab still a key player?”. A review
Grechukhina K.S., Sukhova M.V., Kolyago E.M., Filonenko D.A., Zhukova L.G.
Brain metastases in her2-positive breast cancer: new opportunities for systemic therapy
Artamonova E.V., Manziuk L.V.
Real-world experience with trastuzumab deruxtecan in patients with metastatic HER2-positive breast cancer and HER2-positive gastric cancer: A retrospective study
Evdokimov V.I., Bloshchinenko A.A., Abolmasov A.E., Vilensky A.A., Laskov M.S.
The effect of combinated treatment of a metastatic HER2-positive stomach cancer
Khvastunov R.A., Nenarokomov A.Y., Tolstopiatov S.E., Babina K.G.
Following in the footsteps of SABCS 2022: top 12 advanced breast cancer studies that could change our clinical practice: A review
Kolyadina I.V.
HER2-positive disseminated gastric and gastro-oesophageal junction adenocarcinoma: forecast, clinical course, treatment
Besova N.S.
Features of response to modern neoadjuvant chemotherapy with dual anti-HER2 blockade (trastuzumab and pertuzumab) in the patients with HER2-positive breast cancer stage II–III
Morozov D.A., Kolyadina I.V., Poddubnaya I.V., Ganshina I.P., Khokhlova S.V., Kоmetova V.V., Rodionov V.V.
Personalized approach to HER2-positive advanced breast cancertherapy
Stenina M.B.
1 - 16 of 16 Items

Search tips:

  • Search terms are case-insensitive
  • Common words are ignored
  • By default only articles containing all terms in the query are returned (i.e., AND is implied)
  • Combine multiple words with OR to find articles containing either term; e.g., education OR research
  • Use parentheses to create more complex queries; e.g., archive ((journal OR conference) NOT theses)
  • Search for an exact phrase by putting it in quotes; e.g., "open access publishing"
  • Exclude a word by prefixing it with - or NOT; e.g. online -politics or online NOT politics
  • Use * in a term as a wildcard to match any sequence of characters; e.g., soci* morality would match documents containing "sociological" or "societal"